Rob Dillard

DocwireNews

In persistent <a href="https://www.docwirenews.com/conference-coverage/houston-acc-2021/catheter-ablation-atrial-fibrillation-heart-failure-secondary-outcomes/">atrial fibrillation</a> (AFib) patients, increased soluble suppression of tumorigenicity 2 (sST2) is a strong marker of recurrence after radiofrequency ablation, according to a study published in Frontiers in Cardiovascular Medicine.&nbsp;In this study, researchers analyzed baseline plasma levels of sST2 from 210 patients with persistent AFib (n = 117) and paroxysmal AFib (n = 93) patients. The population were followed up for 15 months after ablation. The researchers used multivariable Cox regression relationship between circulating sST2 and recurrence was assessed by multivariable Cox regression, while cutoff values of sST2 were determined using operating characteristic curve. To assess the relationship between baseline sST2 level and left atrial volume index (LAVI), the investigative team used multivariate linear regression analysis. They conducted sST2 measurements at 24 hours, 6 months, and 15 months of ablation.According to the results of the study, sST2 was linked with with left atrial volume index (LAVI) in the persistent AFib group, and elevated sST2&nbsp; was observed to independently increased the risk of recurrence of AFib when adjusted for co-variables. In contrast, elevated sST2 cannot predict recurrence in paroxysmal AFib, the researchers noted.The study did have several limitations. First, the study was only carried out in one center, and with a relatively small cohort. Second, the researchers noted, the IHC and WB experiments were done on left atrial appendages taken from patients presenting with a different pathology (AFib combined with valvular heart disease). Third, they further noted, is no direct assessment of atrial fibrosis by using MRI.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
New Research: Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation: Objective: A more extensively fibrotic left atrium contributes to atrial fibrillation&hellip; <a href="https://t.co/vLDP9u3eYv">https://t.co/vLDP9u3eYv</a> <a href="https://twitter.com/hashtag/cardiovascular?src=hash&amp;ref_src=twsrc%5Etfw">#cardiovascular</a>
&mdash; Frontiers in Cardiovascular Medicine (@FrontCVMedicine) <a href="https://twitter.com/FrontCVMedicine/status/1405708851425333257?ref_src=twsrc%5Etfw">June 18, 2021</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;&ldquo;In persistent AFib, circulating sST2 &ge; 39.25 ng/ml was predictive of recurrence after primary ablation. Furthermore, atrial myofibroblasts were likely a cellular source of circulating sST2, which might serve as an important biomarker for the degree atrial fibrosis. Inhibiting circulating sST2 might be useful as an adjuvant treatment to improve outcomes of catheter ablation for persistent AFib,&rdquo; the researchers concluded.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Circulating Soluble Suppression of Tumorigenicity 2 Robust Predictor of Recurrence in Atrial Fibrillation

Atrial Fibrillation

In persistent atrial fibrillation (AFib) patients, increased soluble suppression of tumorigenicity 2 (sST2) is a strong marker of recurrence after radiofrequency ablation, ...

Circulating Soluble Suppression of Tumorigenicity 2 Robust Predictor of Recurrence in Atrial

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe